Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rocatinlimab versus placebo in adults with prurigo nodularis
NL-OMON59432Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Rocatinlimab dose arm(s) with Placebo (2 arms). Primary endpoint: Reduction from baseline in weekly average of daily itching score. Started Dec 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NL-OMON59432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59432.